Retatrutide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Retatrutide

Also known as: LY3437943, triple hormone receptor agonist, GIP/GLP-1/glucagon triple agonist

Synthetic triple receptor agonist peptide (GIP/GLP-1/glucagon receptor agonist)

Research chemicalLast updated: October 31, 2026Based on 25 peer-reviewed studies

What it is

Retatrutide is an investigational weight-loss drug in Phase 3 clinical trials, designed for obesity and type 2 diabetes. It activates three hormone pathways simultaneously — producing some of the largest weight reductions seen in clinical trials to date. Not FDA-approved; under active Phase 3 development.

The scientific side

Retatrutide (LY3437943) is a novel synthetic peptide that acts as a triple agonist simultaneously activating three hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) (PMIDs: 41090431, 37366315, 37385280). Through GLP-1R agonism, retatrutide increases insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake. GIP receptor agonism provides complementary incretin effects that enhance glycemic control and weight loss. Glucagon receptor agonism promotes energy expenditure and fatty acid oxidation, contributing to additional weight and liver fat reduction (PMIDs: 42858523, 40563436). The molecule increases adenylyl cyclase activity and elevates cyclic AMP (cAMP) levels through all three cognate receptors. In isolated human atrial preparations, retatrutide increased force of contraction in a concentration-dependent manner via cAMP-mediated signaling through GLP-1R, GIPR, and GCGR. Mechanistically, retatrutide also reduces circulating ANGPTL3/8 complex concentrations — an effect attributed to GCGR agonism — which may contribute to reductions in triglycerides and LDL-C. Pharmacokinetic data from Phase 1/2 trials indicate dose-proportional pharmacokinetics and a mean half-life of approximately 6 days, supporting once-weekly dosing.

Class: Synthetic triple receptor agonist peptide (GIP/GLP-1/glucagon receptor agonist)

Administration & storage

Administration
Subcutaneous injectiononce weekly (PMID: 37366315)Subcutaneous injectiononce weekly (PMID: 37385280)Subcutaneous injectiononce weekly (PMID: 38858523)Subcutaneous injectiononce weekly (PMID: 42250575)Subcutaneous injectiononce weekly (PMID: 41090431)Subcutaneous injectiononce weekly (PMID: 41160422)
Storage
Storage conditions for retatrutide are not described in the reviewed abstracts.
Cautions
Retatrutide is an investigational compound; as of the reviewed literature it is not FDA-approved for any indication. Use outside of supervised clinical trials is unregulated and carries unknown risks.,Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) were the most commonly reported adverse effects across Phase 1, 2, and 3 trials, were dose-related, and were partially mitigated by lower starting doses and slower dose escalation (PMIDs: 37366315, 37385280, 42250575).,Dose-dependent increases in heart rate were observed in the Phase 2 obesity trial, peaking at Week 24 and declining thereafter.,No severe hypoglycemia was reported in the Phase 2 trials in T2D or the Phase 3 T2D trial; however, two deaths occurred in the Phase 3 trial (both in the 4 mg group, assessed as unrelated to study drug).,Unregulated injectable peptides including retatrutide purchased outside of clinical or prescriptive channels may carry risks of product contamination, manufacturing impurities, and inaccurate dosing.,Sterile technique is essential for any injectable preparation to prevent contamination.

Legal & regulatory status

US FDA

Not approved as of the reviewed literature period; described as investigational/under clinical development (Phase 2 and Phase 3 trials ongoing). One abstract characterizes it as an 'investigational triple-agonist'…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification